Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin PK in Hepatic Impairment
NCT05101265Phase 1Recruiting
- Sponsor
- PharmaMar
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of lurbinectedin in solid tumor (advanced stage) (4 arms), sponsored by PharmaMar. Primary endpoints: Total plasma dose-normalized Cmax, Total plasma dose-normalized AUC0-48h and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05101265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101265.